HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.

AbstractPURPOSE:
These studies explored questions related to the potential use of Laromustine in the treatment of solid tumors and in combination with radiotherapy.
MATERIALS AND METHODS:
The studies used mouse EMT6 cells (both parental and transfected with genes for O(6)-alkylguanine-DNA transferase [AGT]), repair-deficient human Fanconi Anemia C and Chinese hamster VC8 (BRCA2(-/-)) cells and corresponding control cells, and EMT6 tumors in mice assayed using cell survival and tumor growth assays.
RESULTS:
Hypoxia during Laromustine treatment did not protect EMT6 cells or human fibroblasts from this agent. Rapidly proliferating EMT6 cells were more sensitive than quiescent cultures. EMT6 cells expressing mouse or human AGT, which removes O(6)-alkyl groups from DNA guanine, thereby protecting against G-C crosslink formation, increased resistance to Laromustine. Crosslink-repair-deficient Fanconi Anemia C and VC8 cells were hypersensitive to Laromustine, confirming the importance of crosslinks as lethal lesions. In vitro, Laromustine and radiation produced additive toxicities to EMT6 cells. Studies using tumor cell survival and tumor growth assays showed effects of regimens combining Laromustine and radiation that were compatible with additive or subadditive interactions.
CONCLUSIONS:
The effects of Laromustine on solid tumors and with radiation are complex and are influenced by microenvironmental and proliferative heterogeneity within these malignancies.
AuthorsSara Rockwell, Yanfeng Liu, Helen A Seow, Kimiko Ishiguro, Raymond P Baumann, Philip G Penketh, Krishnamurthy Shyam, Oluwatoyin M Akintujoye, Peter M Glazer, Alan C Sartorelli
JournalInternational journal of radiation biology (Int J Radiat Biol) Vol. 88 Issue 3 Pg. 277-85 (Mar 2012) ISSN: 1362-3095 [Electronic] England
PMID22111842 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Hydrazines
  • Sulfonamides
  • laromustine
  • O(6)-Methylguanine-DNA Methyltransferase
Topics
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Cell Hypoxia (drug effects, radiation effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects, radiation effects)
  • Cell Survival (drug effects, radiation effects)
  • Combined Modality Therapy
  • Cricetinae
  • DNA Repair (drug effects, radiation effects)
  • Humans
  • Hydrazines (pharmacology, therapeutic use)
  • Mammary Neoplasms, Animal (drug therapy, metabolism, pathology, radiotherapy)
  • Mice
  • Neoplasms (drug therapy, metabolism, pathology, radiotherapy)
  • O(6)-Methylguanine-DNA Methyltransferase (metabolism)
  • Radiation Tolerance (drug effects)
  • Sulfonamides (pharmacology, therapeutic use)
  • Tumor Microenvironment (drug effects, radiation effects)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: